Onderzoeker
Yannick Vandenplas
- Disciplines:Farmacologie niet elders geclassificeerd, Farmaco-economie
Affiliaties
- Klinische Farmacologie en Farmacotherapie (Afdeling)
Lid
Vanaf13 aug 2019 → Heden
Projecten
1 - 1 of 1
- Beleid voor best-value biologische geneesmiddelen in België.Vanaf3 sep 2019 → 18 sep 2023Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
1 - 10 van 11
- A Belgian policy framework for best-value biological medicines(2023)
Auteurs: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis(2023)
Auteurs: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- How to select a best-value biological medicine? A practical model to support hospital pharmacists(2022)
Auteurs: Liese Barbier, Yannick Vandenplas, Isabelle Huys, Arnold Vulto
Pagina's: 2001 - 2011 - Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study(2022)
Auteurs: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- How to balance valuable innovation with affordable access to medicines in Belgium?(2022)
Auteurs: Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Evelien De Sutter, Rosanne Janssens, Teodora Lalova-Spinks, Robbe Saesen, et al.
- Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care(2022)
Auteurs: Yannick Vandenplas, Liese Barbier, Steven Simoens, Arnold Vulto, Isabelle Huys
- Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians(2021)
Auteurs: Liese Barbier, Yannick Vandenplas, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis(2021)
Auteurs: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Informing Patients about Biosimilar Medicines: The Role of European Patient Associations(2021)
Auteurs: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Biosimilars in Oncology – Part II: Considerations about the clinical use of oncology biosimilars(2020)
Auteurs: Liese Barbier, Evelien Moorkens, Yannick Vandenplas, Arnold Vulto
Pagina's: 286 - 292